Ticker League

Vertex Pharmaceuticals (VRTX) Profit Bridge

See what drove Vertex Pharmaceuticals's net income from TTM through Q1 2025 to TTM through Q1 2026 — every line ranked by dollar impact, from revenue gains to taxes.

TTM

Revenue YoY

+10.41%

Operating Income YoY

+743.38%

Net Income YoY

+538.70%

Net Margin Δ

+4431 bps

Net income bridge for Vertex Pharmaceuticals (VRTX) — TTM through Q1 2026 vs TTM through Q1 2025

Δ Net income: $5.33B+538.70%

Profit bridge breakdown for Vertex Pharmaceuticals (VRTX) — TTM through Q1 2026 vs TTM through Q1 2025

  • Prior Net Income−$988.90M
  • Revenue$1.16B
  • Cost of Revenue−$130.20M
  • Operating Expenses$4.49B
  • Other Income / Expense−$52.20M
  • Income Tax−$138.70M
  • Net Income$4.34B
Identity check: drivers reconcile to ΔNI within $0.00
Want the full P&L structure?Income Statement Waterfall

Frequently asked questions

Data & methodology